

**ICMJE DISCLOSURE FORM**

Date: 12/14/2022

Your Name: Prakirthi Yerram

Manuscript Title: Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

Manuscript number (if known) AOL-22-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| <b>Time frame: Since the initial planning of the work</b> |  |   |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | None  |   |
|   |  | This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 | Institution   |
|   |  | Cycle for Survival Equinox and the Leukemia & Lymphoma Society.                               | Institution   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |

**Time frame: past 36 months**

|    |  |          |            |
|----|--|----------|------------|
| 2  | Grants or contracts from any entity (if not indicated in item #1 above).                                     | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 3  | Royalties or licenses  | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 4  | Consulting fees  | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 6  | Payment for expert testimony   | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 7  | Support for attending meetings and/or travel   | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 8  | Patents planned, issued or pending   | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 11 | Stock or stock options   | Roche    | Individual |
|    |  |          |            |
|    |  |          |            |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 13 | Other financial or non-financial interests   | ___ None |            |
|    |  |          |            |
|    |  |          |            |

**Please summarize the above conflict of interest in the following box:**

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. CG was supported by grants from Cycle for Survival Equinox and the Leukemia & Lymphoma Society.

I am a current employee of Flatiron Health, an independent subsidiary of the Roche group and holds stock in Roche.

**Please place an "X" next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

**ICMJE DISCLOSURE FORM**

Date: 12/14/2022

Your Name: Samantha Reiss

Manuscript Title: Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

Manuscript number (if known) AOL-22-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| <b>Time frame: Since the initial planning of the work</b> |  |   |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | None  |   |
|   |  | This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 | Institution   |
|   |  | Cycle for Survival Equinox and the Leukemia & Lymphoma Society.                               | Institution   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |

**Time frame: past 36 months**

|    |  |          |            |
|----|--|----------|------------|
| 2  | Grants or contracts from any entity (if not indicated in item #1 above).                                     | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 3  | Royalties or licenses  | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 4  | Consulting fees  | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 6  | Payment for expert testimony   | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 7  | Support for attending meetings and/or travel   | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 8  | Patents planned, issued or pending   | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 11 | Stock or stock options   | ___ None | Individual |
|    |  | Roche    |            |
|    |  |          |            |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ___ None |            |
|    |  |          |            |
|    |  |          |            |
| 13 | Other financial or non-financial interests   | ___ None |            |
|    |  |          |            |
|    |  |          |            |

**Please summarize the above conflict of interest in the following box:**

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. CG was supported by grants from Cycle for Survival Equinox and the Leukemia & Lymphoma Society.

I am a current employee of Flatiron Health, an independent subsidiary of the Roche group and holds stock in Roche.

**Please place an "X" next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

**ICMJE DISCLOSURE FORM**

Date: 12/14/2022

Your Name: Lisa Modelevsky

Manuscript Title: Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

Manuscript number (if known) AOL-22-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| <b>Time frame: Since the initial planning of the work</b> |  |   |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | None  |   |
|   |  | This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 | Institution   |
|   |  | Cycle for Survival Equinox and the Leukemia & Lymphoma Society.                               | Institution   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |

**Time frame: past 36 months**

|    |  |          |  |
|----|--|----------|--|
| 2  | Grants or contracts from any entity (if not indicated in item #1 above).                                     | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 3  | Royalties or licenses  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 4  | Consulting fees  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 6  | Payment for expert testimony   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 7  | Support for attending meetings and/or travel   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 8  | Patents planned, issued or pending   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 11 | Stock or stock options   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 13 | Other financial or non-financial interests   | ___ None |  |
|    |  |          |  |
|    |  |          |  |



**Please summarize the above conflict of interest in the following box:**

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. CG was supported by grants from Cycle for Survival Equinox and the Leukemia & Lymphoma Society.

I have no other disclosures

**Please place an "X" next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

**ICMJE DISCLOSURE FORM**

Date: 12/14/2022

Your Name: Lauren Schaff

Manuscript Title: Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

Manuscript number (if known) AOL-22-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| <b>Time frame: Since the initial planning of the work</b> |  |   |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | None  |   |
|   |  | This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 | Institution   |
|   |  | Cycle for Survival Equinox and the Leukemia & Lymphoma Society.                               | Institution   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |

**Time frame: past 36 months**

|    |  |          |  |
|----|--|----------|--|
| 2  | Grants or contracts from any entity (if not indicated in item #1 above).                                     | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 3  | Royalties or licenses  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 4  | Consulting fees  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 6  | Payment for expert testimony   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 7  | Support for attending meetings and/or travel   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 8  | Patents planned, issued or pending   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 11 | Stock or stock options   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 13 | Other financial or non-financial interests   | ___ None |  |
|    |  |          |  |
|    |  |          |  |

**Please summarize the above conflict of interest in the following box:**

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. CG was supported by grants from Cycle for Survival Equinox and the Leukemia & Lymphoma Society.

I have no other disclosures

**Please place an "X" next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

**ICMJE DISCLOSURE FORM**

Date: 12/14/2022

Your Name: Anne S Reiner

Manuscript Title: Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

Manuscript number (if known) AOL-22-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| <b>Time frame: Since the initial planning of the work</b> |  |   |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | None  |   |
|   |  | This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 | Institution   |
|   |  | Cycle for Survival Equinox and the Leukemia & Lymphoma Society.                               | Institution   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |

**Time frame: past 36 months**

|    |  |          |  |
|----|--|----------|--|
| 2  | Grants or contracts from any entity (if not indicated in item #1 above).                                     | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 3  | Royalties or licenses  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 4  | Consulting fees  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 6  | Payment for expert testimony   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 7  | Support for attending meetings and/or travel   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 8  | Patents planned, issued or pending   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 11 | Stock or stock options   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 13 | Other financial or non-financial interests   | ___ None |  |
|    |  |          |  |
|    |  |          |  |

**Please summarize the above conflict of interest in the following box:**

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. CG was supported by grants from Cycle for Survival Equinox and the Leukemia & Lymphoma Society.

I have no other disclosures

**Please place an "X" next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

**ICMJE DISCLOSURE FORM**

Date: 12/14/2022

Your Name: Katherine S Panageas

Manuscript Title: Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

Manuscript number (if known) AOL-22-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| <b>Time frame: Since the initial planning of the work</b> |  |   |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | None  |   |
|   |  | This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 | Institution   |
|   |  | Cycle for Survival Equinox and the Leukemia & Lymphoma Society.                               | Institution   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |



**Time frame: past 36 months**

|    |  |          |  |
|----|--|----------|--|
| 2  | Grants or contracts from any entity (if not indicated in item #1 above).                                     | ___ None |  |
| 3  | Royalties or licenses  | ___ None |  |
| 4  | Consulting fees  | ___ None |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None |  |
| 6  | Payment for expert testimony   | ___ None |  |
| 7  | Support for attending meetings and/or travel   | ___ None |  |
| 8  | Patents planned, issued or pending   | ___ None |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | ___ None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ___ None |  |
| 11 | Stock or stock options   | ___ None |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ___ None |  |
| 13 | Other financial or non-financial interests   | ___ None |  |

**Please summarize the above conflict of interest in the following box:**

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. CG was supported by grants from Cycle for Survival Equinox and the Leukemia & Lymphoma Society.

I have no other disclosures

**Please place an "X" next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

**ICMJE DISCLOSURE FORM**

Date: 12/14/2022

Your Name: Christian Grommes

Manuscript Title: Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

Manuscript number (if known) AOL-22-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| <b>Time frame: Since the initial planning of the work</b> |  |   |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | None  |   |
|   |  | This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 | Institution   |
|   |  | Cycle for Survival Equinox and the Leukemia & Lymphoma Society.                               | Institution   |
|   |  |   |   |
|   |  |   |   |
|   |  |   |   |

**Time frame: past 36 months**

|    |  |                           |            |
|----|--|---------------------------|------------|
| 2  | Grants or contracts from any entity (if not indicated in item #1 above).                                     | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 3  | Royalties or licenses  | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 4  | Consulting fees  | ONO, BTG, ROCHE, and Kite | Individual |
|    |  |                           |            |
|    |  |                           |            |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 6  | Payment for expert testimony   | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 7  | Support for attending meetings and/or travel   | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 8  | Patents planned, issued or pending   | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 11 | Stock or stock options   | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |
| 13 | Other financial or non-financial interests   | ___ None                  |            |
|    |  |                           |            |
|    |  |                           |            |

**Please summarize the above conflict of interest in the following box:**

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. CG was supported by grants from Cycle for Survival Equinox and the Leukemia & Lymphoma Society.

I have received consultation fees from ONO, BTG, ROCHE, and Kite

**Please place an "X" next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**